Psoriasis Skin and Connective Tissue Diseases
Conditions
Interventions
This is a randomized, controlled, three-arm, double-blind clinical trial. Participants and the dermatologists responsible for outcome assessment will remain blinded to group allocation. A total of 90
Sponsors
Faculdade de Medicina da Universidade de Brasília - UNB
Universidade de Brasilia
Eligibility
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: men and women aged 60 to 80 years, inclusive, at the time of enrollment; diagnosed with psoriasis; able to read, understand, and sign the Informed Consent Form (ICF); willing to be photographed and sign a photography authorization form; and willing and able to comply with all study instructions, complete study procedures as scheduled, and adhere to study restrictions
Exclusion criteria
Exclusion criteria: participation in any other ongoing clinical study; individuals with any acute or chronic medical condition, except for type 2 diabetes mellitus, including dermatological disorders, that, in the opinion of the Principal Investigator, may place them at risk or interfere with study outcomes; uncontrolled chronic or severe diseases and conditions that would typically preclude participation in a clinical trial, such as cancer, AIDS, diabetes, renal failure, severe mental illness, or drug/alcohol dependence; individuals considered unreliable or unlikely to be available throughout the study period; individuals with a history of allergic reactions, skin sensitization, and/or known allergies to cosmetic ingredients, personal care products, sunscreens, or related products; immunocompromised individuals; individuals who initiated hormone replacement therapy within the three months preceding the screening visit; women who have been using oral contraceptives for less than three months prior to the screening visit, changed their contraceptive method within the three months preceding the screening visit, or plan to modify their contraceptive regimen during the study period; women who are known to be pregnant, breastfeeding, or planning to become pregnant within six months (participants who become pregnant during the study must immediately notify the Principal Investigator and will be withdrawn from the study); and individuals who are unable to communicate or cooperate adequately with the Principal Investigator or study staff
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the progression of clinical and immunosenescence markers, including PASI score, circulating cytokine levels, telomere length, CDKN2 and TP53 gene expression, and the proportions of lymphocyte subpopulations, at baseline and at the end of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
BR
Contacts
Public ContactJuliana Carvalho
Universidade de Brasilia
Outcome results
None listed